Skip to main content
. 2019 Nov 27;295(1):191–211. doi: 10.1074/jbc.RA119.009650

Figure 5.

Figure 5.

Reduction of endogenous 4.1R+17b and E-cadherin at AJs of EGFP–4.1R−17b–expressing cells but not that of EGFP–4.1R+17b–expressing cells. MDCK cells were transfected with EGFP–4.1R135 (A), EGFP–4.1R80 (B), EGFP–4.1R135+17b (C), or EGFP–4.1R80+17b (D) and immunofluorescently-stained for the presence of the endogenous 4.1R+17b with an anti-ex17b and AJs with anti-E-cadherin or anti-β-catenin antibody in XY and XZ sections 36 h post-transfection and revealed with Zeiss microscopy. Regions were selected that contained a mix of transfected and untransfected cells. A and B, EGFP–4.1R135 (A) or EGFP–4.1R80 (B) displace endogenous 4.1R+17b forms at cell–cell contacts (upper), diminish E-cadherin signals at the AJs (middle), but do not alter the localization of β-catenin (lower) at the AJs in expressing cells. Green, EGFP–4.1R135 or EGFP–4.1R80; red, ex17b, E-cadherin, or β-catenin. Bar, 10 μm. C and D, expression of EGFP–4.1R135+17b (C) or EGFP–4.1R80+17b (D) does not alter the endogenous 4.1R+17b, E-cadherin, and β-catenin at the AJs of expressing cells compared with that of nonexpressing cells. Green, EGFP–4.1R135+17b or EGFP–4.1R80+17b; red, ex17b, E-cadherin, or β-catenin. Bar, 10 μm.